 |
|
|
| |
Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance-associated variants at baseline
|
| |
| |
Reported by Jules Levin
International Workshop on HIV & Hepatitis Virus
Drug Resistance and Curative Strategies,
Melia Sitges, Spain, 5-9 June 2012
Veerle Van Eygen,1 Kim Thys,1 Johan Vingerhoets,1 Carl Van Hove,2 Laurence T Rimsky,1 Jeroen Aerssens,1 Gaston R Picchio3
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Janssen Pharmaceutica, Beerse, Belgium; 3Janssen Research & Development LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
